Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

Conditions: PASC Post Acute Sequelae of COVID 19; Long COVID Interventions: Drug: 1500 Valacyclovir 200 Celecoxib; Drug: 750 Valacyclovir 200 Celecoxib; Drug: Placebo Sponsors: Bateman Horne Center Recruiting

https://clinicaltrials.gov/study/NCT06316843

Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

More News: Celebrex | COVID-19 | Research | SARS | Valtrex